Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 18 years of age~* Chronic plaque PSO for at least 6 months prior to the Screening Visit~* Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Investigator's Global Assessment (IGA) score \>=3 on a 5-point scale~* Subject is a candidate for systemic PSO therapy and/or phototherapy~* Female subject of child bearing potential must be willing to use highly effective method of contraception~Exclusion Criteria:~* Subject has a known hypersensitivity to any excipients of bimekizumab or adalimumab~* Subject has an active infection (except common cold), a serious infection, or a history of opportunistic or recurrent chronic infections~* Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection~* Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection~* Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study~* Subject has had previous exposure to adalimumab~* Presence of active suicidal ideation or positive suicide behavior~* Presence of moderately severe major depression or severe major depression~* Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimekizumab Arm 1 (Type: EXPERIMENTAL): Subjects will receive bimekizumab dose regimen 1 for 56 weeks. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
- Bimekizumab Arm 2 (Type: EXPERIMENTAL): Subjects will receive bimekizumab dose regimen 1 for 16 weeks and will proceed with bimekizumab dose regimen 2 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
- Adalimumab Arm (Type: ACTIVE_COMPARATOR): Subjects will receive adalimumab for 24 weeks and will then receive bimekizumab dose regimen 1 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.

Based on this trial design, predict the completion outcome and termination type (if applicable).